The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Nancy M. Allen Allen LaPointe

Duke Clinical Research Institute

Durham

North Carolina

USA

[email]@mc.duke.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Duke Clinical Research Institute, Durham, North Carolina, USA. 2007 - 2010
  • School of Medicine, Duke University, Duke Clinical Research Institute, Durham, USA. 2009
  • Duke Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC 27715, USA. 2002 - 2007

References

  1. In-hospital management of patients with atrial flutter. LaPointe, N.M., Sun, J.L., Kaplan, S. Am. Heart J. (2010) [Pubmed]
  2. Changes in beliefs about medications during long-term care for ischemic heart disease. Allen LaPointe, N.M., Ou, F.S., Calvert, S.B., Melloni, C., Stafford, J.A., Harding, T., Alexander, K.P., Peterson, E.D. Am. Heart J. (2010) [Pubmed]
  3. Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. Allen LaPointe, N.M., Chen, A.Y., Roe, M.T., Cohen, D.J., Diercks, D.B., Hoekstra, J.W., Fesmire, F.M., Gibler, W.B., Ohman, E.M., Peterson, E.D. Am. J. Cardiol. (2009) [Pubmed]
  4. Use of beta-blockers in patients with an implantable cardioverter defibrillator. LaPointe, N.M., Stafford, J.A., Pappas, P.A., Al-Khatib, S.M., Anstrom, K.J. Ann. Pharmacother (2009) [Pubmed]
  5. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease. Allen LaPointe, N.M., Zhou, Y., Stafford, J.A., Hernandez, A.F., Kramer, J.M., Anstrom, K.J. Am. J. Cardiol. (2009) [Pubmed]
  6. Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. Allen Lapointe, N.M., Sun, J.L., Kaplan, S., d'Almada, P., Al-Khatib, S.M. Am. J. Cardiol. (2008) [Pubmed]
  7. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. LaPointe, N.M., Chen, A.Y., Alexander, K.P., Roe, M.T., Pollack, C.V., Lytle, B.L., Ohman, M.E., Gibler, B.W., Peterson, E.D. Arch. Intern. Med. (2007) [Pubmed]
  8. Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. Allen LaPointe, N.M., Governale, L., Watkins, J., Mulgund, J., Anstrom, K.J. Am. Heart J. (2007) [Pubmed]
  9. Patient receipt and understanding of written information provided with isotretinoin and estrogen prescriptions. Allen LaPointe, N.M., Pappas, P., Deverka, P., Anstrom, K.J. J. Gen. Intern. Med (2007) [Pubmed]
  10. Frequency of high-risk use of QT-prolonging medications. Allen LaPointe, N.M., Curtis, L.H., Chan, K.A., Kramer, J.M., Lafata, J.E., Gurwitz, J.H., Raebel, M.A., Platt, R. Pharmacoepidemiol. Drug. Saf (2006) [Pubmed]
  11. Multifaceted intervention to promote beta-blocker use in heart failure. LaPointe, N.M., DeLong, E.R., Chen, A., Hammill, B.G., Muhlbaier, L.H., Califf, R.M., Kramer, J.M. Am. Heart J. (2006) [Pubmed]
  12. Knowledge deficits related to the QT interval could affect patient safety. LaPointe, N.M., Al-Khatib, S.M., Kramer, J.M., Califf, R.M. Ann. Noninvasive. Electrocardiol (2003) [Pubmed]
  13. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. LaPointe, N.M., Pamer, C.A., Kramer, J.M. Pharmacotherapy (2003) [Pubmed]
  14. Evaluation of the dofetilide risk-management program. Allen LaPointe, N.M., Chen, A., Hammill, B., DeLong, E., Kramer, J.M., Califf, R.M. Am. Heart J. (2003) [Pubmed]
  15. Patient-reported frequency of taking aspirin in a population with coronary artery disease. Allen LaPointe, N.M., Kramer, J.M., DeLong, E.R., Ostbye, T., Hammill, B.G., Muhlbaier, L.H., McCants, C.B., Chen, A., Califf, R.M. Am. J. Cardiol. (2002) [Pubmed]
  16. Practitioner acceptance of the dofetilide risk-management program. LaPointe, N.M., Kramer, J.M., Weinfurt, K.P., Califf, R.M. Pharmacotherapy (2002) [Pubmed]
 
WikiGenes - Universities